$2.91 Billion is the total value of Tekla Capital Management LLC's 196 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UHS | New | Universal Health Services, Inc.class b | $9,514,000 | – | 71,323 | +100.0% | 0.33% | – |
| GTHX | New | G1 Therapeutics, Inc. | $9,426,000 | – | 391,754 | +100.0% | 0.32% | – |
| CTLT | New | Catalent, Inc. | $8,427,000 | – | 80,025 | +100.0% | 0.29% | – |
| IMAB | New | I-Mabsponsored ads | $8,089,000 | – | 166,896 | +100.0% | 0.28% | – |
| BNTX | New | BioNTech SEsponsored ads | $7,514,000 | – | 68,814 | +100.0% | 0.26% | – |
| REPL | New | Replimune Group, Inc. | $6,684,000 | – | 219,060 | +100.0% | 0.23% | – |
| MORF | New | Morphic Holding, Inc. | $5,667,000 | – | 89,559 | +100.0% | 0.20% | – |
| TVTX | New | Travere Therapeutics, Inc. | $5,315,000 | – | 212,869 | +100.0% | 0.18% | – |
| TCRR | New | TCR2 Therapeutics Inc. | $5,207,000 | – | 235,808 | +100.0% | 0.18% | – |
| ICLR | New | Icon plcshares | $4,633,000 | – | 23,592 | +100.0% | 0.16% | – |
| BBIO | New | BridgeBio Pharma, Inc. | $4,602,000 | – | 74,714 | +100.0% | 0.16% | – |
| PSNL | New | Personalis, Inc. | $4,423,000 | – | 179,731 | +100.0% | 0.15% | – |
| NTLA | New | Intellia Therapeutics, Inc. | $4,268,000 | – | 53,180 | +100.0% | 0.15% | – |
| VIR | New | Vir Biotechnology, Inc. | $4,173,000 | – | 81,400 | +100.0% | 0.14% | – |
| JNCE | New | Jounce Therapeutics, Inc. | $3,926,000 | – | 382,237 | +100.0% | 0.14% | – |
| ARQT | New | Arcutis Biotherapeutics, Inc. | $3,808,000 | – | 131,633 | +100.0% | 0.13% | – |
| MREO | New | Mereo BioPharma Group plcads | $3,361,000 | – | 997,290 | +100.0% | 0.12% | – |
| BDTX | New | Black Diamond Therapeutics, Inc. | $3,202,000 | – | 131,990 | +100.0% | 0.11% | – |
| RCM | New | R1 RCM Inc. | $3,047,000 | – | 123,461 | +100.0% | 0.10% | – |
| XENE | New | Xenon Pharmaceuticals Inc. | $2,970,000 | – | 165,898 | +100.0% | 0.10% | – |
| KALV | New | KalVista Pharmaceuticals, Inc. | $1,285,000 | – | 50,000 | +100.0% | 0.04% | – |
| ONEM | New | 1Life Healthcare, Inc. | $1,222,000 | – | 31,266 | +100.0% | 0.04% | – |
| NKTX | New | Nkarta, Inc. | $954,000 | – | 28,988 | +100.0% | 0.03% | – |
| GMDA | New | Gamida Cell Ltd.shares | $956,000 | – | 118,142 | +100.0% | 0.03% | – |
| VYNE | New | VYNE Therapeutics Inc. | $927,000 | – | 135,395 | +100.0% | 0.03% | – |
| EDIT | New | Editas Medicine, Inc. | $638,000 | – | 15,190 | +100.0% | 0.02% | – |
| DTIL | New | Precision BioSciences, Inc. | $652,000 | – | 63,001 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.